Azathioprine and chlorambucil: mechanism of action and use in ...

35. Bouwes Bavnick J, Hardie D, Green A. The risk of skin cancer in renal transplant recipients in Queensland,
Australia. A follow-up study. Transplantation 1996;61:715-721.
36. Saway P, Heck L, Bonner J, Kirlin J. Azathioprine hypersensitivity. Am J Med 1988 84 960-964.
37. Gilman A, Phillips F. The biological actions and therapeutic applications of β-chloroethyl amines and sulfides.
Science 1946;103:409-415.
38. Goodman L, Wintrobe M, Dameshek W, Goodman J, Gilman A. Nitrogen mustard therapy. Use of methylbis(β-chloroethylamine
hydrochloride) and tris(β-chloroethyl)amine hydrochloride for Hodgkin's disease,
lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 1946;132:126-132.
39. Everett J, Roberts J, Ross W. Aryl-2-halogenoalkylamines. XII: Some carboxylic derivatives of N,N-di-2chloroaethylaniline.
J Chem Soc 1953:2386-2392.
40. Maxwell R, Eckhardt S. Drug discovery: a casebook and analysis. Humana Press, 1990.
41. Hurley L. DNA and its associated processes as targets for cancer therapy. Nature Reviews Cancer 2002;2:188-
200.
42. Tew K. Alkylating Agents. In: DeVita V, Lawrence T, Rosenberg S, editors. Cancer: principles and practice
of oncology. 8th edn. Lippincott Williams & Wilkins, Philadelphia, 2008:407-419.
43. Plumb D. Plumb's Veterinary Drug Handbook. Blackwell Publishing, Stockholm, WI, 2005.
44. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002;3:149-158.
45. Scheinfeld N. A brief primer on treatments of cutaneous T cell lymphoma newly approved or late in
development. J Drugs Dermatol 2007;6:757-760.
46. Holmes R, McGibbon D, Black M. Mycosis fungoides: progression towards Sézary syndrome reversed with
chlorambucil. Clin Exp Derm 1983;8:429-435.
47. Zouboulis C. Extended venous thrombosis in Adamantiades-Behçet’s disease. Eur J Dermatol 2004;14:268-
271.
48. Elbirt D, Asher I, Sthoeger Z. Behçet’s disease - clinical presentation, diagnostic and therapeutic approach.
Harefuah 2002;141:462-467, 497.
49. Torabian S, Fazel N, Knuttle R. Necrobiotic xanthogranuloma treated with chlorambucil. Dermatol Online J
2006;12:11.
50. Hoefnagel J, Vermeer M, Jansen P, Heule F. Primary cutaneous marginal zone B-cell lymphoma. Arch
Dermatol 2005;141:1139-1145.
51. Doherty C, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs 2008;68:1361-1383.
52. Case J, Smith S, Callen J. The use of pulse methylprednisolone and chlorambucil in the treatment of Sweet's
syndrome. Cutis 1989;44:125-129.
53. Shah N, Green A, Elgart G, Kerdel F. The use of chlorambucil with prednisolone in the treatment of
pemphigus. J Am Acad Dermatol 2000;42:85-88.
54. Milligan A, Hutchinson P. The use of chlorambucil in the treament of bullous pemphigoid. J Am Acad
Dermatol 1990;22:796-801.
55. Sinoway P, Callen J. Chlorambucil. An effective corticosteroid-spraing agent for patients with recalcitrant
dermatomyositis. Arthritis Rheum 1993;36:319-324.
56. Thamm D, Vail D. Mast cell tumours. In: Withrow S, Vail D, editors. Small Animal Clinical Oncology. 4th
edn. Saunders Elsevier, St. Louis, 2007:402-424.
57. Taylor F, Gear R, Hoather T, Dobson J. Chlorambucil and prednisolone chemotherapy for dogs with
inoperable mast cell tumours: 21 cases. J Small Anim Pract 2009;50:284-289.
58. White S. Nonsteroidal immunosuppressive therapy. In: Bonagura J, editor. Kirk's Current Veterinary Therapy:
XIII Small Animal Practice. Saunders, Philadelphia, 2000:536-538.
59. Guaguere E, Muller A, Degorce-Rubiales F. Epithelitropic mucocutaneous T cell lymphoma. In: Guaguere E,
Prelaud P, Craig M, editors. A Practical Guide to Canine Dermatology. Kalianxis Publishing, Italy, 2008:493–500.
60. Kristal O, Rassnick K, Gliatto J, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in
dogs. J Vet Intern Med 2004;18:75-80.
55